昂妥昔珠单抗
单克隆抗体 | |
---|---|
种类 | 完整抗体 |
目標 | TEM1 |
臨床資料 | |
ATC碼 |
|
识别信息 | |
CAS号 | 946415-62-9 |
ChemSpider |
|
UNII | |
化学信息 | |
化学式 | C6532H10050N1726O2054S44 |
摩尔质量 | 147,034.92 g·mol−1 |
昂妥昔珠单抗(INN:Ontuxizumab[1])是一种人源化兔单克隆抗体,[2]设计用于治疗癌症。它与内皮唾液酸蛋白(也称TEM1或CD248)结合。[3]该药物的I期试验已经完成,该药物被美国食品药品监督管理局授予治疗肉瘤的孤儿药地位。目前正处于黑色素瘤、结直肠癌、肉瘤和淋巴瘤的II期试验中。[4]
参考资料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109 (PDF). WHO Drug Information. 2013, 27 (2) [2024-01-23]. (原始内容存档 (PDF)于2022-01-20).
- ^ US 20100260769,Sass PM, Kline B, Nicolaides N, Grasso L, Harley S,「Endosialin binding molecules」,发表于2010-04-08,指定于Morphotek Inc
- ^ Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, et al. Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment. August 2015, 8 (2): 111–8. PMC 4542822 . PMID 26085332. doi:10.1007/s12307-015-0168-8.
- ^ 4.0 4.1 Ontuxizumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-23]. (原始内容存档于2024-01-23).